Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against PepGen Inc. (PEPG)

Core Viewpoint - A securities class action lawsuit has been filed against PepGen Inc. for allegedly making false and misleading statements regarding the effectiveness and safety of its drug PGN-EDO51, as well as the CONNECT2 study's viability for FDA approval [1][2]. Group 1: Allegations and Impact - The lawsuit claims that PepGen misrepresented the effectiveness and safety of PGN-EDO51, leading investors to believe it was more promising than it actually was [2]. - It is alleged that the CONNECT2 study was either dangerous or deficient, which could result in PepGen halting the study, thereby overstating the drug's clinical, regulatory, and commercial prospects [2]. - Following the announcement of disappointing clinical data from the CONNECT1 study, PepGen's stock price dropped by $5.55, or 32.69%, closing at $11.43 per share [4]. Group 2: Clinical Data and Analyst Reactions - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, with a dystrophin increase of only 0.61% of normal, which was disappointing [3]. - Analysts from Stifel and Leerink Partners expressed concerns that the results did not meet PepGen's anticipated threshold of 1% or greater dystrophin expression [3]. Group 3: Legal Proceedings - Investors who acquired shares of PepGen during the class period are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on August 8, 2025 [5].